Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation

dc.creatorSilva, Amanda Karolina Soares
dc.creatorPeixoto, Christina Alves
dc.date2019-04-29T12:59:13Z
dc.date2019-04-29T12:59:13Z
dc.date2018
dc.date.accessioned2023-09-26T23:52:29Z
dc.date.available2023-09-26T23:52:29Z
dc.identifierSILVA, A. K. S.; PEIXOTO, C. A. Role of Peroxisome Proliferator-Activated Receptors in Non-Alcoholic Fatty Liver Disease Inflammation. Cellular and Molecular Life Sciences, v. 75, n. 16, p. 2951–2961, 1 ago. 2018.
dc.identifier1420-9071
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/32817
dc.identifier10.1007/s00018-018-2838-4
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8895141
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (the Brazilian National Council for Scientific and Technological Development) (CNPq; #301777/2012-8) and CAPES/PNPD Program for Silva AKS post-Doc scholarship.
dc.descriptionOverweight and obesity have been identified as the most important risk factors for many diseases, including cardiovascular disease, type 2 diabetes and lipid disorders, such as non-alcoholic fatty liver disease (NAFLD). The metabolic changes associated with obesity are grouped to define metabolic syndrome, which is one of the main causes of morbidity and mortality in industrialized countries. NAFLD is considered to be the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver diseases worldwide. Inflammation plays an important role in the development of numerous liver diseases, contributing to the progression to more severe stages, such as non-alcoholic steatohepatitis and hepatocellular carcinoma. Peroxisome proliferator-activated receptors (PPARs) are binder-activated nuclear receptors that are involved in the transcriptional regulation of lipid metabolism, energy balance, inflammation and atherosclerosis. Three isotypes are known: PPAR-α, PPARδ/β and PPAR-γ. These isotypes play different roles in diverse tissues and cells, including the inflammatory process. In this review, we discuss current knowledge on the role PPARs in the hepatic inflammatory process involved in NAFLD as well as new pharmacological strategies that target PPARs.
dc.description2050-01-01
dc.formatapplication/pdf
dc.languageeng
dc.rightsrestricted access
dc.subjectNAFLD
dc.subjectInflammation
dc.subjectPPARs
dc.subjectAnimais
dc.subjectRegulamento de Expressão Gênica
dc.subjectHumanos
dc.subjectInflamação / genética
dc.subjectInflamação / metabolismo
dc.subjectMetabolismo lipídico / genética
dc.subjectFígado / metabolismo
dc.subjectFígado / patologia
dc.subjectDoença hepática gordurosa não alcoólica / genética
dc.subjectDoença hepática gordurosa não alcoólica / metabolismo
dc.subjectReceptores Ativados por Proliferação de Peroxissoma / classificação
dc.subjectReceptores Ativados por Proliferadores Peroxissomais / metabolismo
dc.subjectIsoformas de Proteína / metabolismo
dc.titleRole of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation
dc.typeArticle


Este ítem pertenece a la siguiente institución